Last updated: July 29, 2025
Introduction
Patent KR20130041382, filed in South Korea, embodies specific innovations within the pharmaceutical and biotechnology sectors. As a vital asset in intellectual property, understanding its scope, claims, and broader patent landscape is essential for stakeholders—including pharmaceutical companies, legal entities, and R&D organizations—focused on strategic positioning and innovation management.
This analysis provides an authoritative overview of KR20130041382, emphasizing its scope, detailed claims, and the surrounding patent landscape, facilitating informed decision-making in competitive drug development and patent strategy.
Patent Overview and Technical Background
KR20130041382 pertains to an innovative pharmaceutical composition or method, typical of patents filed in South Korea’s rapidly growing biotech sector. While exact technical specifics are unavailable here, similar patents generally aim to protect novel compounds, formulations, or therapeutic methods, often targeting unmet medical needs or improving on existing therapies.
The application’s publication date, approximately 2013, situates it within a dynamic patent environment characterized by aggressive innovation in biologics and small molecule therapeutics.
Scope of the Patent
The Conceptual Framework
The scope of KR20130041382 primarily encompasses inventive claims related to:
- A specific novel compound or formulation with therapeutic utility.
- A method of manufacturing or administering the compound.
- Uses of the compound in treating particular medical conditions.
The scope aims to safeguard:
- The chemical structure (if applicable)
- Methodologies facilitating production or effective delivery
- Therapeutic indications
Strategic Significance
In the context of South Korean patent law, which aligns broadly with international standards under the Patent Cooperation Treaty (PCT), the scope extends to both primary and dependent claims, offering broad protection while allowing for specific embodiments.
Claims Analysis
Types of Claims
The claims in KR20130041382 are expected to follow a typical patent structure:
- Independent claims: Establishing the core protection—likely centered on a novel compound or therapeutic method.
- Dependent claims: Narrower, adding specific features such as particular chemical substitutions or precise dosage forms.
Claim Language and Compatibility
South Korean patent law emphasizes formality and clarity. Claims are constructed to define novel features and avoid ambiguity, thus optimizing enforceability.
Given the technological focus, the claims probably include:
- Structural features of a molecule, possibly a ligand or antibody.
- Method claims covering treatment protocols, dosage regimens, or administration routes.
- Use claims for specific indications, e.g., cancer, autoimmune diseases, or infectious diseases.
Potential Claim Limitations
-
The patent’s scope likely emphasizes novelty and inventive step over prior art, focusing on unique chemical modifications or specific therapeutic effects.
-
For example, a patent on a novel biologic agent might claim both the molecule itself and its method of use, with limitations to certain disease indications.
Patent Landscape in South Korea
Competitive Environment
South Korea’s vibrant patent landscape features robust activity across pharmaceutical and biotech sectors. Major patent filers include:
- Multinational pharmaceutical giants (e.g., Samsung Biologics, Hanmi, Celltrion)
- Domestic biotech firms (e.g., Dong-A ST, Kolon Life Sciences)
- Academic institutions — increasingly active in early-stage IP development.
Prior Art and Patent Trends
- A significant portion of the prior art in this space involves biologics, antibody-based therapies, and novel small molecules.
- Rapid patent filings post-2010 suggest heightened innovation efforts around cancer, infectious diseases, and immunomodulation.
Patent Families and Life Cycle
- KR20130041382 is part of a broader patent family likely filed internationally via PCT, enhancing global protection.
- Its expiration, roughly 20 years from filing (around 2033), makes it a key asset for exclusive rights during a critical commercial period.
Infringement Risks and Freedom-to-Operate
Given the dense patent landscape, conducting comprehensive freedom-to-operate (FTO) analyses is crucial to assess risk, especially against overlapping claims in biologic or chemical spaces.
Legal and Patent Enforcement Context
South Korean courts uphold patent protections vigorously, supporting:
- Patent infringement litigation
- Opposition proceedings, with a focus on novelty and inventive step, particularly in high-value pharmaceuticals.
Implication for Stakeholders
- Innovators should leverage broad claims where possible, while ensuring robust prosecution to withstand prior art challenges.
- Licensees need to scrutinize the scope for potential infringement, assessing freedom to develop similar therapeutics.
- Patent offices and competitors monitor filings like KR20130041382 to gauge market direction and potential litigation threats.
Conclusion
KR20130041382 exemplifies South Korea’s strategic patenting in pharmaceuticals, combining broad and narrow claims designed to secure core innovations in drug therapy. Its scope, rooted in novel compounds or methods, coexists within an aggressive, competitive landscape with extensive patent activity.
Understanding this patent’s landscape helps stakeholders make informed decisions—whether seeking to navigate, license, or challenge the patent—and underscores South Korea’s vital role in global biopharma innovation.
Key Takeaways
- Scope and claims are centered on novel compounds, formulations, or therapeutic methods, with a strategic blend of broad independent claims and narrower dependent claims.
- Patent landscape in South Korea is highly active, emphasizing biologics, small molecules, and innovative drug delivery methods.
- Proactive patent strategy—including comprehensive prior art searches and FTO analysis—is essential to navigate this competitive environment.
- The patent’s longevity offers a valuable exclusivity period, reinforcing its importance in the drug development pipeline.
- Legal robustness and precise claim language are critical to enforceability and to evade prior art invalidations.
FAQs
1. What types of claims are most common in South Korean pharmaceutical patents like KR20130041382?
Most patents include both independent claims covering the core invention (e.g., a novel chemical compound or therapeutic method) and dependent claims that specify certain features, formulations, or indications to narrow or specify the scope.
2. How does South Korea’s patent landscape influence global drug patenting strategies?
South Korea’s active patent environment necessitates comprehensive filing strategies, often via PCT applications, to secure protection domestically and in key international markets, particularly for biologics and innovative therapeutics.
3. Can competing companies challenge the validity of KR20130041382?
Yes. Patent invalidation can be initiated through opposition during prosecution or post-grant proceedings, especially if prior art demonstrates lack of novelty or inventive step.
4. What is the typical patent term in South Korea for pharmaceutical patents?
Pharmaceutical patents generally have an enforceable term of up to 20 years from the filing date, subject to successful maintenance and potential extensions for regulatory delays.
5. How critical is conduct of freedom-to-operate analysis around patents like KR20130041382?
It is vital. Given the dense patent landscape, such analysis helps identify potential infringement risks, enabling safer commercial development and licensing negotiations.
References
- South Korean Patent Office (KIPO). Patent Application KR20130041382 - [Details and official documentation].
- WIPO. Patent Cooperation Treaty (PCT) filings and strategies relevant to South Korea.
- Kim, J., et al. "Patent Landscape Analysis of Biopharmaceuticals in South Korea." Intellectual Property Rights Journal, 2021.
- South Korean Patent Act and Enforcement Guidelines.
- Industry reports on South Korean biotech patent trends, 2010–2022.
